240 related articles for article (PubMed ID: 33817709)
1. Medullary thyroid cancer: molecular factors, management and treatment.
Pavlidis E; Sapalidis K; Chatzinikolaou F; Kesisoglou I
Rom J Morphol Embryol; 2020; 61(3):681-686. PubMed ID: 33817709
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
3. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
4. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.
Ilanchezhian M; Khan S; Okafor C; Glod J; Del Rivero J
Horm Metab Res; 2020 Aug; 52(8):588-597. PubMed ID: 32299110
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
6. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
8. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Yeganeh MZ; Sheikholeslami S; Hedayati M
Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
[TBL] [Abstract][Full Text] [Related]
9. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
10. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
12. A primer on the genetics of medullary thyroid cancer.
Larouche V; Akirov A; Thomas CM; Krzyzanowska MK; Ezzat S
Curr Oncol; 2019 Dec; 26(6):389-394. PubMed ID: 31896937
[TBL] [Abstract][Full Text] [Related]
13. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
14. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
Chang CF; Yang WS; Su YN; Wu IL; Chang TC
J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.
Moore SW; Zaahl MG
Pediatr Surg Int; 2008 May; 24(5):521-30. PubMed ID: 18365214
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
17. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
18. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
19. Medullary thyroid carcinoma in children: current state of the art and future perspectives.
Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N
J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078
[TBL] [Abstract][Full Text] [Related]
20. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
